Xolair
E46709
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Xolair canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T363287 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Xolair Context triple: [Genentech, notableProduct, Xolair]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Xolair Target entity description: Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic drug
ⓘ
medication ⓘ monoclonal antibody ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| commonAdverseEffect |
arthralgia
ⓘ
headache ⓘ injection site reaction ⓘ upper respiratory tract infection ⓘ |
| developedBy |
Genentech
ⓘ
Novartis ⓘ |
| hasATCCode | R03DX05 ⓘ |
| hasBlackBoxWarning | risk of anaphylaxis ⓘ |
| hasDosageForm |
prefilled syringe
ⓘ
solution for injection ⓘ vial for reconstitution ⓘ |
| hasDrugClass |
anti-IgE antibody
ⓘ
immunomodulator ⓘ |
| hasGenericName | omalizumab ⓘ |
| hasMolecularTarget | circulating IgE ⓘ |
| hasRouteOfAdministration |
subcutaneous
ⓘ
subcutaneous injection ⓘ |
| indicatedFor |
patients with chronic spontaneous urticaria refractory to H1-antihistamine treatment
ⓘ
patients with inadequately controlled moderate to severe persistent asthma ⓘ patients with positive skin test or in vitro reactivity to a perennial aeroallergen ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| marketedBy |
Genentech
ⓘ
Novartis ⓘ |
| mechanismOfAction |
binds to free IgE
ⓘ
prevents IgE from binding to high-affinity IgE receptors (FcεRI) ⓘ reduces allergic inflammatory response ⓘ |
| reduces |
expression of FcεRI receptors on mast cells and basophils
ⓘ
free IgE levels ⓘ |
| regulatoryApprovalYear |
2003 (FDA, asthma)
ⓘ
2014 (FDA, chronic idiopathic urticaria) ⓘ |
| requiresMonitoring |
asthma control
ⓘ
hypersensitivity reactions ⓘ signs and symptoms of anaphylaxis ⓘ |
| seriousAdverseEffect |
anaphylaxis
ⓘ
eosinophilic conditions ⓘ hypersensitivity reaction ⓘ serum sickness ⓘ |
| targets |
IgE
ⓘ
immunoglobulin E ⓘ |
| usedFor |
allergic asthma
ⓘ
chronic idiopathic urticaria ⓘ chronic spontaneous urticaria ⓘ moderate to severe allergic asthma ⓘ nasal polyps ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Xolair Description of subject: Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.